Expertise in
5
conditions

Yanyan H. Liu

No 1 Eastern Jianshe Road, 
Zhengzhou, CN 
Expertise in
5
conditions
No 1 Eastern Jianshe Road, 
Zhengzhou, CN 

Overview

Yanyan Liu practices practicing medicine in Zhengzhou, China.

Liu is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Atrial Myxoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Orchiectomy.

They are actively involved in clinical research, co-authoring 140 peer reviewed articles and participating in 6 clinical trials.

Locations

No 1 Eastern Jianshe Road, Zhengzhou, 450052, China
Other Locations
No.127 Dongming Road, Zhengzhou, 450001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Single Arm, Multi-center, Phase II Clinical Trial of VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
A Single Arm, Multi-center, Phase II Clinical Trial of VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Enrollment Status: Completed
Publish Date: April 09, 2026
Intervention Type: Drug
Study Drugs: Bortezomib, Rituximab, Epirubicin, Cyclophosphamide, Prednisone
Study Phase: Phase 2
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: LOXO-305
Study Phase: Phase 2
Single-arm, Multi-center and Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Single-arm, Multi-center and Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug
Study Drugs: Camrelizumab, Epirubicin, Vincristine, Dacarbazine
Study Phase: Phase 2
A Single Arm, Multi-center, Phase Ib Clinical Trial of PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
A Single Arm, Multi-center, Phase Ib Clinical Trial of PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drugs: Parsaclisib, Chidamide
Study Phase: Phase 1
A Single-arm, Multi-center, Phase II Clinical Trial of R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Medium to High Risk/High Risk Diffuse Large B Cell Lymphoma
A Single-arm, Multi-center, Phase II Clinical Trial of R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Medium to High Risk/High Risk Diffuse Large B Cell Lymphoma
Enrollment Status: Completed
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Lenalidomide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone, Methotrexate
Study Phase: Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
View 5 Less Clinical Trials

140 Total Publications

A Percentage of Residual Viable Tumor Outperforms Traditional AJCC Staging in Oral Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy.
A Percentage of Residual Viable Tumor Outperforms Traditional AJCC Staging in Oral Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy.
Journal: Annals of surgical oncology
Published: July 10, 2026

Frequently Asked Questions about Yanyan H. Liu

Is Yanyan H. Liu a top-rated expert for Atrial Myxoma?

MediFind is an objective health platform that identifies experts based on real-world data. Yanyan H. Liu is classified as an Advanced expert for Atrial Myxoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yanyan H. Liu participate in research or clinical trials?

Yes. Yanyan H. Liu has published 140 articles and abstracts on conditions like Atrial Myxoma. You can view a list of Yanyan H. Liu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
      View All 32 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile